secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001193125-24-180754
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam appoints McKenna and Joustra to board; Slootweg resigns
--------------------------------------------------------------------

- Sander Slootweg resigned from the Board effective July 16, 2024; no disagreement cited.
- Wouter Joustra (Forbion general partner) and Mark C. McKenna (Mirador CEO) appointed as temporary non-executive directors.
- McKenna granted options for 72,500 ordinary shares at $18.81 per share, vesting over 3 years.
- McKenna also joins audit and compensation committees; Joustra brings capital markets and venture experience.
- Appointments effective immediately; formal ratification expected at next annual general meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/0001193125-24-180754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524180754/d744813d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-180754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer